Get the Stockscreener App
8.90
6.59%
0.55
Pre-market:
8.83
-0.07
-0.79%
Aura Biosciences Inc stock is traded at $8.90, with a volume of 5.88M.
It is up +6.59% in the last 24 hours and up +36.09% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$8.35
Open:
$8.48
24h Volume:
5.88M
Relative Volume:
15.70
Market Cap:
$571.38M
Revenue:
-
Net Income/Loss:
$-106.19M
P/E Ratio:
-4.9112
EPS:
-1.8122
Net Cash Flow:
$-85.19M
1W Performance:
+27.87%
1M Performance:
+36.09%
6M Performance:
+63.60%
1Y Performance:
+50.34%
1-Day Range:
$8.43
$9.535
1-Week Range:
$6.6495
$9.535
52-Week Range:
$4.345
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
8.90 | 571.38M | 0 | -106.19M | -85.19M | -1.8122 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
Aura Biosciences Announces $39.6 Million Public Offering of Common Stock and Pre-Funded Warrants – Underwriting Agreement with Leerink Partners, TD Securities, and Evercore Group - Minichart
Aura Biosciences Completes Major Underwritten Equity Financing - TipRanks
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Aura Biosciences closes $299.4 million public offering By Investing.com - Investing.com India
Aura Biosciences (NASDAQ: AURA) boosts cash runway with $280.8M raise and buyback - Stock Titan
Aura Biosciences Closes $299.4 Million Public Offering to Advance Precision Therapies for Solid Tumors - Quiver Quantitative
Aura raises $299M as underwriters take full extra-share option - Stock Titan
Aura Biosciences (NASDAQ: AURA) offers 39.6M shares, repurchase $39M - Stock Titan
Norwegian Cruise Line, Aura Biosciences and other big stocks moving lower in Monday's pre-market session - MSN
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences Announces Stock Repurchase Agreement with Shareholder - TipRanks
Aura Biosciences (NASDAQ: AURA) plans 6.9M-share Matrix buyback - Stock Titan
Aura Biosciences launches public offering of common stock By Investing.com - Investing.com India
Aura Biosciences Appoints New CEO as Phase 3 CoMpass Trial for Belzupacap Sarotalocan Nears Enrollment Completion - Minichart
Aura Biosciences names Natalie Holles as new CEO By Investing.com - Investing.com South Africa
Aura Biosciences names Natalie Holles as new CEO - Investing.com UK
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big - Benzinga
Aura Biosciences prices $260.3M stock offering at $6/share - Investing.com
Aura Biosciences prices $260M stock, warrant offering - MSN
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants - The Manila Times
Aura Biosciences announces pricing of $260 million public offering of common stock and pre-funded warrants - marketscreener.com
Aura Biosciences prices $260.3M stock offering at $6/share By Investing.com - Investing.com UK
Aura Biosciences Inc. Announces Pricing of $260.3 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Aura raises $260.3M, earmarks part to buy out Matrix stake - Stock Titan
Orion Corporation: Managers’ transactions – Kari Jussi Aho - Weekly Voice
Aura Biosciences Appoints Natalie Holles CEO as Phase 3 Trial Nears Enrollment Completion - citybiz
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Aura Biosciences (AURA) offers stock and pre-funded warrants; plans possible Matrix buyback - Stock Titan
Aura Biosciences Names Natalie Holles as CEO, Plans Public Offering - marketscreener.com
Aura Biosciences Advances CoMpass Phase 3 Trial Progress - TipRanks
Aura Biosciences launches public offering of common stock - Investing.com
New Aura Biosciences (NASDAQ: AURA) CEO as Phase 3 CoMpass trial nears enrollment - Stock Titan
Aura seeks fresh capital with stock sale and pre-funded warrants - Stock Titan
New Aura CEO arrives as eye cancer trial nears enrollment completion - Stock Titan
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Aura Biosciences, Inc. Announces Board and Executive Changes, Effective April 30, 2026 - marketscreener.com
Are medical stocks lagging Aura Biosciences (AURA) this year? - MSN
AURA SEC FilingsAura Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
(AURA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
Aura Biosciences, Inc. (AURA) just flashed golden cross signal: Do you buy? - MSN
Is Aura Biosciences (AURA) stock outpacing its medical peers this year? - MSN
Aura Bio (AURA) Stock: Stability Check (Smart Money Flows) 2026-04-22Crowd Entry Signals - Cổng thông tin điện tử tỉnh Lào Cai
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year? - Yahoo Finance
Aura Biosciences (NASDAQ: AURA) outlines 2026 vote on directors and auditor - Stock Titan
Aura Bio (AURA) Stock Forecast (Smart Money Exits) 2026-04-20Trending Momentum Stocks - Xã Thanh Hà
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect? - Yahoo Finance
(AURA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):